Tocilizumab for juvenile idiopathic arthritis: a single-center case series.
Evrim Kargın ÇakıcıSemanur OzdelDoğan ŞimşekÖzlem AydoğEvrim Kargın CakıcıGökçe Gür CanTulin GungorMehmet BülbülPublished in: Sao Paulo medical journal = Revista paulista de medicina (2020)
Tocilizumab therapy should be considered for treating patients with diagnoses of pJIA or sJIA who are resistant to non-biological DMARDs and/or other biological therapies.